I hereby certify that this correspond. . . being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 16930-004500US

Assistant Commissioner for Patents Washington, D.C. 20231

on <u>February 28,2001</u>

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. marshall

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Richard B. Murphy

Application No.: 09/418,814

Filed: October 15, 1999

For: TARGETED VECTORS

Examiner: Gai Lee

Art Unit:

1632

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

Richard B. Murphy

Application No.: 09/418,814

Page 2

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action.

Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

This Petition is submitted in triplicate.

Respectfully submitted,

Matthew E. Hinsch Reg. No. P-47,651

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

MEH:jmm

SF 1194242 v1

FORM PTO-1449 (Modified)			Attorney Docket No.: 16930-004500US Application No.: 09/418,8			.: 09/418,814		
	NTS AND PUBL		Applicant: Richard B. Murphy					
	INFORMATION Use several sheets		Filing Date: October 15, 1999 Group: 1632					
Reference Desig	gnation		J.S. PATENT DOCUME	ENTS		Page 1		
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)		
1	4,569,794	2/11/86	Smith, et al.					
2	5,723,287	3/3/98	Russell, et al.					
3	5,871,727	2/16/99	Curiel					
4	5,882,877	3/16/99	Gregory, et al.					
5	5,846,782	12/8/98	Wickham, et al.					
6	5,965,541	10/12/99	Wickham, et al.					
7	5,932,210	8/3/99	Gregory, et al.					
		707	DIGINAL MANAGEMENT OF COLUMN	<u></u>		1		
			EIGN PATENT DOCU		T	1		
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)		
			,					
	07	THER ART (Incl	uding Author, Title, Date	e, Pertinent Pages,	Etc.)	<u></u>		
8	Arnberg, et al., "Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract"; Virology, 227:239-244 (1997)							
9	Douglas, et al., "Targeted gene delivery by tropism-modified adenoviral vectors"; Nature Biotechnology, Vol. 14, 1574 (Nov. 1996)							
10	Douglas, et al., "A system for the propagation of adenoviral vectors with genetically modified receptor specificities"; Nature Biotechnology, Vol. 17, 470-475 (May 1999)							
11	Harris, et al., "Strategies for targeted gene therapy"; TIG, Vol. 12, No. 10 400-405 (Oct. 1996)							
12	Michael, et al.; "Binding-incompetent Adenovirus Facilities Molecular Conjugate-mediated Gene Transfer by the Receptor-mediated Endocytosis Pathway"; <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 10 6866-6869 (April 1993)							
13	Michael, et al., "Addition of a short peptide ligand to the adenovirus fiber protein"; Gene Therapy, 2:660-668 (1995)							
14	Nilson, et al., "Targeting of retroviral vectors through protease-substrate interactions"; Gene Therapy, 3:280-286 (1996)							
15	Ohno, et al., "Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A"; Nature Biotechnology, Vol. 15, 763-767 (August 1997)							
16	Stevenson, et al., "Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein"; Journal of Virology, Vol. 71, No. 6 4782-4790 (June 1997)							
17	Watkins, et al., "The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery"; Gene Therapy, 4:1004-1012 (1997)							
18	Wickham, et al., "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins"; Journal of Virology, Vol. 71, No. 11 8221-8229 (Nov. 1997)							
XAMINER			DATE CONSIDERED)		•		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Murphy

Application No.: Not Assigned

Filed: August 22, 2003

For: TARGETED VECTORS

Examiner:

Not Assigned

Art Unit:

Not Assigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references on the PTO Form 1449 filed 07/10/01, can be found in Application No. 09/687,930, filing date 10/13/00 (attorney docket number 016930 004520). Copies of the references on the Form 1449 filed 02/28/01, can be found in Application No. 09/418,814, filing date 10/15/99 (Attorney Docket No. 016930-004500US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Application No.: Not Assigned

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the abovenoted Deposit Account.

Respectfully submitted,

Matthew E. Hinsch Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

MEH:jmm

60024234 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016930-004520US

Assistant Commissioner for Patents Washington, D.C. 20231

on July 10, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. Marshall

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Richard B. Murphy

Application No.: 09/687,930

Filed: October 13, 2000

For: TARGETED VECTORS

Examiner:

Art Unit:

1635

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The references cited on attached forms PTO-1449 are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references on the PTO Form 1449 filed 2/28/01 can be found in Application No. 09/418,814, filed 10/15/99 (Attorney Docket No. 016930-004500US). Copies of the references on the PTO-1449 for the instant application are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the related PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Richard B. Murphy

Application No.: 09/687,930

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Matthew E. Hinsch Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

MEH:jmm

SF 1245253 v1

202162201	40.0 6. 11.0. 10		D. 1.11.0460		T				
FORM PTO-1449 (Modified)			Attorney Docket No.: 016930-004520US Application No.: 09/687,930			.: 09/687,930			
	NTS AND PUBL		Applicant: Richard B. Murphy						
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Filing Date: October 13, 2000		Group: 1635				
Reference Desi	gnation	1	U.S. PATENT DOCUMENT	S		Page 1			
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)			
1	5,439,829	8/8/95	Anderson, et al.						
2	5,885,808	3/23/99	Spooner, et al.						
3	5,705,151	1/6/98	Dow, et al.						
		FOF	L REIGN PATENT DOCUME	NTS					
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)			
<u></u>	O	THER ART (Incl	uding Author, Title, Date, P	ertinent Pages,	Etc.)				
4	Eck, et al., "Gene-based therapy"; Goodman & Gilman's The Pharmacological Basis of Therapeutics – Ninth Edition McGraw-Hill pp. 77-101 (1996)								
5	Kabanov & Kabanov "DNA Complexes with Polycations for the Delivery of Genetic Material into Cells" Bioconjugate Chem., Vol. 6, pp. 7-20 (1995)								
6	Verma, et al. "Gene Therapy – promises, problems and prospects"; Nature, Vol. 389, pp. 239-242 (September 1997)								
EXAMINER	DATE CONSIDERED								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.